Therapeutic options in advanced prostate cancer;Options therapeutiques dans le cancer avance de la prostate

Praxis

Volumn 86, Issue 44, 1997, Pages 1734-1739

  Schmid, H P ^a,b   Bitton, A ^a  

^a Clinique Urologique   (Switzerland)

^b Hopital de l'Ile   (Switzerland)

Author keywords

chemotherapy; hormonal therapy; palliative therapy; prostatic carcinoma

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; NILUTAMIDE; STRONTIUM 89; TRIPTORELIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CARDIOVASCULAR DISEASE; DIARRHEA; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; IRRADIATION; LIVER TOXICITY; MALE; MALE SEXUAL DYSFUNCTION; NAUSEA; ORCHIECTOMY; PROSTATE CANCER; SHORT SURVEY; SURVIVAL; THROMBOEMBOLISM; WATER RETENTION; ADJUVANT CHEMOTHERAPY; CANCER STAGING; MORTALITY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; PALLIATIVE CARE; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0031590335     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Stamey T. A., McNeal J. E.: Adenocarcinoma of the prostate. In: Campbell's Urology, Walsh P. C., Retik A. B., Stamey T. A., Vaughan E. D. Jr. (eds.). W. B. Saunders, Philadelphia, 6th ed. Vol. 2, chapter 29, p. 1159-1221, 1992.
2. Epidemiology of cancer in Switzerland. Registre vaudois des Tumeurs, Levi F., La Vecchia C., Lucchini F., Randimbison L. (eds.). Lausanne, 1994.
3. Smith J. A., Jr.: New methods of endocrine management of prostatic cancer. J. Urol. 137: 1-10, 1987.
4. Kuhn J.-M., Billebaud T., Navratil H., Moulonguet A., Fiet J., Grise P., Louis J.-F., Costa P., Husson J.-M., Dahan R., Bertagna C., Edelstein R.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (Buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (Nilutamide). New Engl. J. Med. 321: 413-418, 1989.
5. Byar D. P.: The Veterans Administration Cooperative urological Research Groups's studies of cancer of the prostate. Cancer, 32: 1126-1130 1973.
6. Fossa S. D., Hosbach G., Paus E.: Flutamide in hormone-resistant prostatic cancer. J. Urol. 144: 1411-1414, 1990.
7. Kelly W. K., Scher H. I.: Prostate specific antigen decline after antiandrogen withdrawal. The Flutamide withdrawal syndrome. J. Urol. 149: 607-609, 1993.
8. Studer U. E., Altwein J. E., Bartsch G.: Aspekte zu den möglichen hormonellen Therapien des Prostatakarzinoms. Urologe [A]. 30: 310-316, 1991.
9. Benson R. C. Gill G. M.: Estramustine phosphate compared with diethylstilbestrol. Am. J. Clin. Pathol. 9: 341-351, 1986.
10. Rübben H., Dijkman G., Ferrari P., Fournier G., Hirao Y, Kirk D., Scher H., Schmid H.-P.: Treatment of hormone resistant prostate cancer. First International Consultation on Prostate Cancer (WHO-UICC). Monaco, June 20-22, 1996.
11. Eberle J., Böhlen D., Fügen M., Studer U. E.: Unblutige Prostatabehandlung mit hochintensivem fokussiertem Ultraschall (HIFU). Schweiz. Med. Wochenschr. 126: 1385-1392, 1996.